Advertisement
Product › Details
Budesolv
Status | 2018-10-19 development p3 start | |
Organisation | Marinomed Biotech AG (VSE: MARI) | |
Marinomed Biotech AG. (10/19/18). "Press Release: Initiation of First Marinosolv Clinical Trial (Ph III)".
Marinomed Biotech AG is proud to announce the initiation of their Ph III clinical trial “BDS_18_01” with their first Marinosolv-based investigational medicinal product, “Budesolv 10 micrograms, nasal spray”. This nasal spray will be the first budesonide-based treatment for allergic rhinitis (hay fever) that delivers the active substance in dissolved form, thereby allowing treatment with a lower dose of budesonide than marketed products in a preservative-free configuration. The patent-protected development product will be tested for the indication of allergic rhinitis in the setting of the clinical research facility VCC (Vienna Challenge Chamber), the first and world-leading study center that performs clinical allergy trials under controlled and reproducible conditions in Vienna (www.vcc.at).
[Photo] The “Budesolv 10” study team during the initiation visit at the Vienna Challenge Chamber. Left to right: Dr. Reinhard Riedlsperger, Mag. Martina Görner, CRS Riedlsperger GmbH; Dr. Patrick Lemell, Dr. Petra Zieglmayer, Ing. Rene Zieglmayer, Vienna Challenge Chamber; Dr. Nicole Unger-Manhart, Dr. Eva Prieschl-Grassauer, Dr. Andreas Goessl, Mag. Sabine Grohmann, Marinomed Biotech AG
Record changed: 2023-07-10 |
Advertisement
More documents for bronchospasmolytics & asthma drugs
- [1] AstraZeneca plc. (11/1/21). "Press Release: AstraZeneca to Transfer Global Rights for Eklira and Duaklir to Covis Pharma"....
- [2] Sterna Biologicals GmbH & Co. KG. (1/7/21). "Press Release: Sterna Biologicals Raises further EUR 10.0 Million (approx. USD 11.9 Million) in Series A – 2nd Closing Private Placement". Marburg....
- [3] Sterna Biologicals GmbH & Co. KG. (5/26/20). "Press Release: Sterna Biologicals Secures EUR 12.0 Million (approx. USD 13.0 Million) in Private Placement". Marburg....
- [4] Abionic S.A.. (9/5/19). "Press Release: Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests". Lausanne....
- [5] Marinomed Biotech AG. (1/29/19). "Press Release: Marinomed Sets Offer Price at 75 Euro per Share (Adhoc-News)"....
- [6] Marinomed Biotech AG. (11/28/18). "Press Release: Viennese Biotech Company Marinomed Demonstrates the Benefits of Its Patented Marinosolv Technology"....
- [7] Boehringer Ingelheim. (2/16/17). "Press Release: US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children". Ingelheim....
- [8] Boehringer Ingelheim. (2/15/17). "Press Release: Boehringer Ingelheim and Weill Cornell Medicine Announce New Collaboration to Discover Next Generation COPD Treatments". Ingelheim....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top